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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not topical 
corticosteroids prevent and/or reduce symptoms and severity of radiation dermatitis in breast 
cancer patients receiving radiation therapy to the chest wall.  
Study Design: Review of three double blind randomized controlled clinical trials (RCTs) 
published in 2002, 2007, and 2011 
Data Sources: Three peer-reviewed RCTs were found using PubMed. These studies compared 
topical corticosteroid use against various placebos in the treatment of radiation dermatitis 
Outcomes Measured: Severity of radiation dermatitis as reported using quality of life 
questionnaires, Skindex scores, and Radiation Therapy Oncology Group (RTOG) scaling. 
Significant outcomes were evaluated through the use of p-values and t-tests.  
Results: Schmuth et al (2002) found significant difference between the two treatment arms for 
embarrassment (p<0.05) and approached significance for dimensions of fear (p=0.06) and 
physical discomfort (p=0.057). Furthermore, while all dimensions worsened in the dexpanthenol 
treated group, only four of seven dimensions worsened in the corticosteroid group. In Miller et al 
(2011) itching, irritation, the persistence of symptoms, the recurrence of toxicity symptoms, and 
annoyance with dermatitis were all reduced by a statistically significant fraction in the treatment 
group compared with the placebo group in the Skindex-16. The total Skindex-16 score, however, 
did not reach statistical significance between the MMF arm and placebo arm with a p=0.07. In 
Omidvari et al (2007) all patients developed some degree of radiation dermatitis. However, 
patients receiving betamethasone had less severe acute radiation dermatitis than the petrolatum 
receiving or control groups throughout the course of the study; this difference was only 
significant by the end of the third week (p=0.027).  
Conclusion: Conflicting results from these three RCTs demonstrates that the use of topical 
corticosteroids in the prevention and treatment of radiation dermatitis is inconclusive  
Key Words: Corticosteroids, Radiation Dermatitis, Breast Cancer, Chest wall Irradiation  
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INTRODUCTION 
 With an increase in technology and screening, there is now better detection and treatment 
for breast cancer. While there is great benefit in the improved management of breast cancer, it is 
essential to consider the subsequent side effects of treatment and how best to manage those. 
Radiation therapy, for example is used in definitive, preoperative, and postoperative or palliative 
treatment in the management of breast cancer.
1
 Because of the increase in radiation therapy there 
has also been an increase in cases of radiation dermatitis, an acute injury within hours to weeks 
after radiation exposure as a result of structural tissue damage, generation of short-lived free 
radicals, irreversible double stranded breaks in nuclear and mitochondrial DNA, and initiation of 
an inflammatory response in the epidermis and dermis.
2
 The exact mechanism of radiation 
induced inflammation is not fully understood, but research to date suggests that fibroblasts are a 
key cell type responsible for the late or delayed effect of radiation.
2
  
Care for this side effect is essential because without reduction in the cosmetic and 
uncomfortable disturbance of radiation dermatitis from therapy, patients often become non-
compliant with appropriate breast cancer treatment.
1
 Due to the variance in severity and response 
to skin treatments, there are no specific guidelines on the number of visits each year for radiation 
dermatitis. Regardless, with an increase in cases of radiation dermatitis (affecting about 87% of 
patients receiving radiation
1
), it is very fortunate that mid-level practitioners, like physician 
assistants, are capable of managing these effects of radiation.  
 In the treatment of any dermatitis, it is necessary to consider the treatment options to 
reduce discomfort, cosmetic disturbances, and recurrence. Unfortunately, there is currently no 
treatment of choice to benefit all patients with radiation dermatitis
1,3
, making it necessary for 
practitioners to be aware of all pharmacologic as well as non-pharmacologic management 
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strategies for managing the dermatitis. Though there are several different recommendations for 
treatment, all studies imply the importance of maintaining appropriate hygiene and avoidance of 
obvious irritants. The affected skin, for example, should remain clean and dry after washing with 
lukewarm water, and mild, synthetic soaps. Patients must avoid skin irritants including sun 
exposure, perfumes and alcohol based lotions, and instead use unscented, lanolin-free, water 
based moisturizers. Loose fitting clothes will also benefit the patient in order to avoid friction 
injuries to the affected skin.
1,3,4,5
 
 After considering the number of simple recommendations for their radiation dermatitis, 
patients and practitioners must choose among the assortment of topicals used in the treatment of 
this conditions. Aloe vera, calendula, petrolatum-based emollients, trolamine-containing 
formulations, topical corticosteroids, and sucralfate cream are the most commonly suggested 
topicals
1
; no general agreement, however, exists concerning how to treat or prevent radiation 
dermatitis.
3
 Though there are a number of options to choose from, this selective EBM review 
seeks to explore the potential benefits of using topical corticosteroids as the sole topical 
treatment for radiation dermatitis. Topical corticosteroids, if beneficial in the prevention and 
treatment of radiation induced dermatitis, are a good option as a topical treatment because they 
are both affordable, ranging from $27 to $42 (in the reviewed studies)
6,7,8
, and have limited 
additional side effects.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not topical 
corticosteroids prevent and/or reduce symptoms and severity of radiation dermatitis in breast 
cancer patients receiving RT to the chest wall.  
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METHODS 
Three double blind randomized controlled studies were used in this review. Each study 
followed a group of women who had previously had surgical treatment for breast cancer and 
were to undergo radiation therapy (RT). Over the course of their RT, topical corticosteroids were 
introduced into the experimental groups. The specific topical corticosteroid, dose, and 
application duration varied across the studies, as did the structure of each control group; the 
commonality, however, was the absence of corticosteroid cream application for the comparison 
control group. After the application of the creams to the irradiated skin for a specified duration, 
patients were asked to be assessed for or report the outcome of their treatment based on the 
severity of their radiation dermatitis.  
Key words used in search included corticosteroids, radiation dermatitis, breast cancer, 
and chest wall irradiation. The chosen articles were all written in English and published in peer-
reviewed journals between 2002 and 2011. Each was found through PubMed database, and 
selected based on its relevance to my initial clinical question and its ability to be correlated to the 
outcome in question. The inclusion criteria consisted of RCT’s and a population of female breast 
cancer patients with previous surgical treatment and were receiving RT. Women receiving other 
therapies for their radiation dermatitis were excluded, as were women with a history of other skin 
conditions, or inflammatory breast carcinoma. In the analysis of each trial, p-values, t-tests, 
and/or Kruskal-Wallis tests were utilized to determine the summary of statistical significance of 
topical corticosteroid use.  
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Table 1: Demographics & Characteristics of Included Studies  
 
 
OUTCOMES MEASURED 
Each breast cancer patient who successfully adhered to all experimental procedures, was 
asked to either complete a quality of life questionnaire/Skindex-score survey, or was evaluated 
with RTOG scaling to determine the results of topical corticosteroid use during and after RT. 
Study Type #Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventions 
Omidvari 
(2007)
1 
RCT 58 20-
70 
Female pts who 
underwent 
modified radical 
mastectomy and 
chemo for stage II 
or III and needed 
RT. Without hx of 
RT, DM or 
systemic CTD 
Patients who were 
receiving concurrent 
chemotherapy and 
radiation or were on 
systemic 
corticosteroids  
7 Betamethasone 
0.1%  
Schmuth 
(2002)
3 
RCT 31 18-
80  
Women receiving 
RT for breast 
cancer after breast 
conserving surgery   
No prior history of 
radiation dermatitis 
or RT to same area; 
pts with skin 
conditions a/w barrier 
defect or those 
receiving systemic 
corticosteroids 
2 Methylprednis
olone 0.1% 
Miller 
(2011)
4 
RCT 176 >18  Invasive breast or 
ductal carcinoma 
in situ; continuous, 
definitive, or 
adjuvant external 
beam RT to whole 
breast as part of 
breast conservation 
therapy or to breast 
wall as part of 
postmastectomy 
RT  
Inflammatory 
carcinoma, allergy to 
mometasone, 
imidazolidinyl urea, 
or formadelhyde; use 
of leukotriene 
inhibitors or OTC 
med with 
hydrocortisone/ 
corticosteroid prep; 
pregnant or breast 
feeding; bilateral 
breast carcinoma 
10 Mometasone 
fuoate 0.1% 
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These assessments successfully measured the impact of the RT on the skin in terms of severity, 
patient symptoms, and morbidity associated with the skin changes.  
 Schmuth et al (2002) assessed patients’ quality of life (QOL) using a medical outcome 
study 36-item short form health survey as well as the Skindex survey. The former was developed 
to identify general physical and mental components of health related QOL with 36 items 
measuring eight general health dimensions.
3
 The Skindex scoring system was slightly different, 
as it was developed to identify skin disease specific health related QOL rather than that for 
general health. This 61-item version included two physical (discomfort and limitations) and three 
major psychosocial (cognitive, social, and emotional) dimensions as they related to QOL in 
regards to skin disease.
3
  Scores for both assessments of QOL were standardized to 100, with the 
higher scores indicating a better outcome.
 
 In Miller et al’s study (2011), patient reported outcomes were measured using the 
Skindex-16 and the skin toxicity assessment. The skin toxicity assessment tool is a skin-specific 
instrument that consisted of a provider assessment as well as patient reported discomfort. The 
patient completed QOL assessment consisted of six questions, with responses ranging from 0 
(poor QOL) to 10 (best QOL).  
 Rather than assessing acute radiation dermatitis with QOL surveys like the previously 
explained studies, Omidvari et al. utilized RTOG acute radiation morbidity scoring criteria for 
the skin. With each visit throughout the study, patient’s irradiated skin was scored grades 0-4 
based on the level of dermatitis experienced by the patient. Grade 0 referred to no skin changes 
over baseline, or no radiation dermatitis. Grades 1-4 represented skin changes ranging from 
erythema, dry desquamation, and decreased sweating to ulceration, hemorrhage, and necrosis. In 
terms of patient outcome and perspective, grade 1 was considered less bothersome than the 
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obvious pain experienced by patients with grade 4 radiation dermatitis.
1
 Thus, the higher the 
grade assigned to the patient, the worse radiation dermatitis was to be experienced by the patient.  
RESULTS 
 Three double blind RCT’s compared the severity of radiation dermatitis in female, breast 
cancer patients receiving standardized RT after surgical treatment with topical corticosteroid 
treatment as compared to other topical therapies for the skin condition. Miller et al (2011) used 
patients receiving the non-steroidal topical cream as the control group while the other two studies 
had a control group of individuals using no topical treatment. Omidvari et al (2007) and Schmuth 
et al (2002), thus had three groups of individuals participating in the study; those receiving 
topical corticosteroids, a non-steroidal cream, and a group without topical cream treatment. The 
inclusion and exclusion criteria of all three studies were relatively similar, with small differences 
primarily seen in exclusion criteria (Table 1).
1,3,4
 Women receiving concurrent chemotherapy and 
radiation were excluded from the studies because there is an additive response between 
combined chemo and RT, leading to an increase in severity of radiation dermatitis.
9 
 Data from all trials were reported as continuous data and could not be converted into a 
dichotomous format; therefore, calculations evaluating tolerability, adverse events, and treatment 
effects could not be computed. Patients in the studies received written information and consented 
to participate in each trial prior to randomization. Because the women were free to withdraw, 
each study lost a few participants over the course of the treatment for reasons that were not 
shared. The losses, however, were minimal, ranging from 0-2 patients from a given group.
1,3,4
  
In Schmuth et al (2002), a preliminary cohort of 15 patients who did not receive topical 
therapy served as a control group. After obtaining the baseline data from the initial control 
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cohort, a subsequent cohort of patients was recruited and randomized to one of the two groups in 
a double blind fashion; one group receiving 0.5% dexpanthenol and the other the interventional 
treatment in question, 0.1% methylprednisolone. The study population was selected from 
consecutive patients attending the Department of Radiation Therapy in Innsbruck. Twenty three 
patients were randomized into one of the two groups applying a specific type of cream. Two 
patients withdrew from the methylprednisolone group due to either inadequate adherence to 
treatment (n=1) or patients’ request (n=1). At the completion of the study, there were 11 patients 
using the topical dexpanthenol and 10 patients using the methylprednisolone. The severity of 
each patients’ radiation dermatitis was monitored weekly throughout the study; with six weeks of 
fractionated RT and two weeks of follow-up after its completion.
3
  
Clinical and functional parameters with questionnaire based QOL assessment of patient’s 
own experience of their disease and response to therapy was performed using the SF-36 and 
Skindex QOL assessments. Of the 21 patients who completed the study, only 16 and 17 patients 
for the Skindex and SF-36 questionnaires, respectively, were usable, yielding final response rates 
of 76% and 81%, respectively. An unpaired t-test was first used to calculate differences in QOL 
scores between the treatment arms. Post-treatment QOL scores were then compared with the 
pretreatment baseline scores by the paired t-test; a p value of <0.05 was considered significant. 
In both the SF-36 and Skindex inventories, scores largely deteriorated from pretreatment to post 
treatment, reflecting appearance of radiation dermatitis in all subjects. Severity of change, 
however, differed between those treated with corticosteroids versus dexpanthenol. While all 
dimensions worsened in the dexpanthenol treated group, only four of seven dimensions 
worsened in the corticosteroid group, indicating that topical corticosteroids may in part reverse 
negative impact of radiation dermatitis. The difference between the two treatment groups was 
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significant for the dimension of embarrassment and approached significance for the dimensions 
of fear and physical discomfort.
3
  
Table 2: Difference in post-treatment v. pretreatment QOL scores for 0.1% 
Methylprednisolone v. 0.5% Dexpanthenol  
 P values  
Embarrassment   <0.05 (value not given) 
Fear  0.06  
Physical discomfort  0.057 
 
Miller et al (2011) recruited 176 patients between September and December 2007, with a 
follow up period of two weeks after RT completion. Of the 176 patients 90 were randomly 
assigned to the treatment group applying 0.1% mometasone fuorate and 86 were randomly 
assigned to the control group with the application of a placebo cream. After randomization, 5 
patients in the MMF arm and 2 patients in the placebo arm declined participation, for 169 
eligible patients. Data was missing for 3 patients, leaving 166 patients eligible for evaluation. 
The secondary endpoints of patient reported skin toxicity (outcome measures using Skindex-16 
and skin toxicity assessment tool) and QOL were analyzed by comparing the mean responses 
between the study arms using the Kruskal-Wallis test. Itching, irritation, the persistence of 
symptoms, the recurrence of toxicity symptoms, and annoyance with dermatitis were all reduced 
by a statistically significant fraction in the treatment group compared with the placebo group in 
the Skindex-16. The total Skindex-16 score, however, did not reach statistical significance 
between the MMF arm and placebo arm with a p=0.07. The patients in the MMF arm also 
reported less discomfort and burning, less itching, and less redness using the Skin Toxicity 
Assessment tool and symptom experience diary.
4 
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Table 3: Patient-reported maximum Skindex-16, Skin Toxicity Assessment Tool, and 
Symptom Experience Diary toxicity scores 
 Maximum Skindex-16 score  
Toxicity Characteristic MMF (n=83) Placebo (n=83)  p value 
Itching 2.3 3.1 0.008 
Irritation 2.6 3.4 0.01 
Persistence/recurrence of sx 2.3 3.0 0.02 
Annoyance of sx 1.2 1.8  0.04 
Total Skindex-16 score 1.4 1.7 0.07 
 Skin Toxicity Assessment score  
Discomfort or burning 1.5 2.1 0.02 
Itching 1.5 2.2 0.002 
 Symptom Experience Diary score  
Redness 5.1 6.8 0.003 
*Lower score indicated less toxicity 
 In Omidvari et al (2007), eligible patients were female patients who previously 
underwent modified radical mastectomy for pathologically proved breast cancer and needed 
treatment with RT. During a three month period, 58 eligible patients were randomly assigned by 
a computer based system to receive petrolatum, bethamethasone 0.1%, or none. Of the 58, seven 
patients failed to complete the study course or were excluded because of declining to participate, 
new onset DM (part of exclusion criteria), or prolonged radiation course due to other causes, 
leaving 51 statistically evaluable cases at the end of the study. Of these 19 were in the 
betamethasone group, 17 in the petrolatum group, and 15 in the control arm.
1
  
 The severity of the patients’ radiation dermatitis was determined using RTOG acute 
radiation morbidity scoring criteria for skin as described earlier in the review. The 
betamethasone acute radiation dermatitis (ARD) scoring was lower throughout the study. The 
data showed that though patients applying topical corticosteroid did have ARD after RT, the 
severity of the condition was lower and with a delayed onset when compared to the other two 
arms of the study. Significant difference, however, was only found at the end of the third week, 
only 26.3% of the betamethasone group with Grade I dermatitis compared with 64.7% and 
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66.7% in the emollient and control arms respectively; these results were considered statistically 
significant with a p-value of 0.027 (statistical significance achieved when p<0.05). Furthermore 
with this data, the numbers needed to treat can be calculated with an NNT=2 patients. At the 
conclusion of the topical treatment, all petrolatum-receiving patients developed Grade II or 
higher ARD. At the same time, all patients had some degree of ARD but betamethasone 
receiving patients had lower mean dermatitis grade than the other two arms. These results, 
however did not reach significance but approached it with p=0.055.
1
  
DISCUSSION 
 Using three double blind RCT’s this systematic review assessed the effects of topical 
corticosteroids in the prevention and treatment of radiation dermatitis. Each article selected 
female breast cancer patients who were undergoing radiation therapy post-surgical treatment for 
their cancer and assessed the severity of radiation dermatitis that resulted from radiation to the 
skin.  The validity and blinding of each RCT was without error, however the sample sizes were 
relatively small despite the low drop-out rate. Furthermore, quality of life was the main 
assessment of patient outcomes in this study, but many others do exist. 
 Since their introduction to dermatologic therapy in 1952, topical corticosteroids have 
become widely available and are very useful in treating numerous skin conditions. When use as 
directed, this topical therapy is safe and very effective. Inappropriate or overuse, however, can 
lead to several topical and systemic side effects that practitioners must be mindful of when 
prescribing the topical medication. All topical corticosteroids, for example, have been shown to 
cause some degree of skin atrophy. Topical corticosteroids are contraindicated as primary 
treatment of bacterial infections because they are known to mask an infection by their 
vasoconstrictive and anti-inflammatory properties, making diagnosis of infections more difficult. 
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Other relative contraindications include Candidal, dermatophyte, and herpetic infections.
10
 Thus, 
despite their broad availability, efficacy, relative low cost, ease of application, and lack of black 
of box warnings, practitioners must be mindful of the risks associated with topical 
corticosteroids.  
CONCLUSION 
 The use of topical corticosteroids has shown inconclusive results in the prevention and 
treatment of radiation dermatitis in breast cancer patients undergoing radiation therapy to the 
chest wall. Though the data is statistically inconclusive, these studies support the notion that 
topical corticosteroids do in fact provide some relief to patients experiencing radiation 
dermatitis. Both Miller et al (2011) and Schmuth et al (2002) provided evidence a decrease in the 
decline of QOL with the use of topical corticosteroids as compared to the control. Likewise, 
Omidvari et al’s (2007) results demonstrated a delay in radiation dermatitis and an overall lower 
grade radiation dermatitis score for those using the betamethasone in comparison to the group.  
 The use of topical corticosteroids in all studies relied on patient compliance and honest 
report of application. Furthermore, the correct amount of the cream may not have been equal for 
all patients throughout the study, possibly altering the true benefits/harms of using the steroid 
creams. In the future, reliability could be improved by clinician administration of the cream in 
order to standardize and control the proper use of the topical treatment. The known anti-
inflammatory effect of corticosteroids on the irradiated skin warrants further investigation. 
Continuing research should continue to compare different treatments for the skin condition to 
come to a consensus on how best to treat radiation dermatitis. Research should also consider the 
duration of experiencing radiation dermatitis after completing radiation therapy. 
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